A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Linaclotide (Linzess)

LINZESS is indicated for the treatment of: • irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older • chronic idiopathic constipation (CIC) in ....

First FDA approval2012-09-08
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$3.07B in CY2024 Part D spend3.8M claims · 1.1M beneficiaries · 329 plans surveyed

Lowest NADAC
$9.02/unit
3 NDCs benchmarked, lowest of all strengths.
Average NADAC
$9.03
Across all dosage forms in distribution.
Highest NADAC
$9.03
Range is tight.
Plans with PA
3 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Linaclotide used for?

LINZESS is indicated for the treatment of: • irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older • chronic idiopathic constipation (CIC) in ....

Is there a generic for Linaclotide?

No. Linaclotide is brand-only with no generic equivalents currently in market.

How much does my plan pay for Linaclotide?

Across 329 Part D plans, Linaclotide averages $9.03/unit (NADAC). Lowest available: $9.02/unit. Highest in distribution: $9.03/unit.

Is Linaclotide on the FDA shortage list?

No. Linaclotide is not currently on the FDA Drug Shortage Database.

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Guanylate Cyclase-C Agonist1 alternative in D1
01
Plecanatide
Brand: Trulance
Lowest NADAC
0Generic mfrs
$183.4MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (3 approvals on file) · NADAC unit costs: CMS NADAC weekly file (3 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.